{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:11:32Z","timestamp":1780697492744,"version":"3.54.1"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuronal ceroid lipofuscinoses, also known as Batten disease, are comprised of a group of genetically heterogenous neurodegenerative conditions, characterized by dementia, epilepsy, motor deterioration, and blindness. The underlying pathology is a dysregulation of lysosomal catabolic protein metabolism, resulting in an accumulation of lipofuscein-like material within the lysosomes in neuronal tissue, which ultimately leads to atrophy in the central nervous system and in the retina. Ceroid lipofuscinosis type 2 (CLN2) is caused by biallelic pathogenic variants in the TPP1 gene, encoding lysosomal tripeptidyl peptidase 1 (TPP-1). The classic late-infantile phenotype of CLN2 disease has an age of onset between 2 and 4 years and manifests with seizures and speech delay, followed by progressive cognitive and motor decline, vision loss, and early death. Vision loss occurs secondary to retinal degeneration and begins in the perifoveal ellipsoid zone, leading to bull\u02bcs eye\n          maculopathy, followed by generalized retinal thinning. In 2017, an intracerebroventricular enzyme replacement therapy (ERT) using recombinant human TPP1 (rhTPP1), cerliponase alfa, was approved as a disease-modifying treatment for CLN2 disease. The therapy slows psychomotor decline but fails to prevent loss of vision. In a canine model of CLN2 disease, intravitreal rhTPP1 was shown to halt retinal degeneration. A prospective, interventional, controlled, open-label compassionate-use study evidenced safety of 0.2\u2009mg intravitreal rhTPP1 every 8 weeks in humans and its efficacy in reducing the rate of macular volume loss in patients who were still in the degenerative phase. One ongoing clinical phase I\/II study is investigating the safety and efficacy of intravitreal rhTPP1 at 4 weekly intervals over 24 months (NCT05152914); another clinical phase II dose escalation trial is planned. In this review, we summarize the current knowledge on ERT for CLN2 retinopathy, complemented with\n          our own experience from an individual treatment. The treatment now appears to be safe and markedly delays retinal degeneration, thereby preserving visual function and increasing the quality of life of the patient. This could be particularly relevant for those patients who were started on intracerebroventricular ERT early and still have good motor and language function. For this patient population, intravitreal ERT could be a valuable bridging therapy until other therapies such as gene therapy become available.<\/jats:p>","DOI":"10.1055\/a-2528-7886","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T23:40:23Z","timestamp":1742859623000},"page":"213-218","source":"Crossref","is-referenced-by-count":3,"title":["Enzyme Replacement Therapy in CLN2-Associated Retinopathy"],"prefix":"10.1055","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1847-3626","authenticated-orcid":false,"given":"Claudia","family":"Priglinger","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital, Ludwig-Maximilians-University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Courage","sequence":"additional","affiliation":[{"name":"Folkh\u00e4lsan Research Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-4901","authenticated-orcid":false,"given":"Esther M.","family":"Maier","sequence":"additional","affiliation":[{"name":"Dr. von Hauner Children\u02bcs Hospital, Section of Inborn Errors of Metabolism, Munich, Germany"},{"name":"Labor Becker MVZ eGbR, Newborn Screening Unit, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/biom11121775","article-title":"Therapeutic Approaches in Lysosomal Storage Diseases","volume":"11","author":"C Fern\u00e1ndez-Pereira","year":"2021","journal-title":"Biomolecules"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ymgme.2012.07.012","article-title":"A shortcut to the lysosome: the mannose-6-phosphate-independent pathway","volume":"107","author":"M F Coutinho","year":"2012","journal-title":"Mol Genet Metab"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.4103\/ijo.IJO_425_22","article-title":"Mucopolysaccharidosis: A broad review","volume":"70","author":"R Nagpal","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of Intraventricular Cerliponase Alfa for CLN2 Disease","volume":"378","author":"A Schulz","year":"2018","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e165076","DOI":"10.1172\/JCI165076","article-title":"A phase I\/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B","volume":"133","author":"N Muschol","year":"2023","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/TCRM.S241048","article-title":"Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy","volume":"16","author":"N Specchio","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41433-021-01594-y","article-title":"An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy","volume":"35","author":"D A Thompson","year":"2021","journal-title":"Eye (Lond)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1006\/mgme.1999.2808","article-title":"Progress in neuropathology of the neuronal ceroid lipofuscinoses","volume":"66","author":"H H Goebel","year":"1999","journal-title":"Mol Genet Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13023-021-01858-6","article-title":"Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa","volume":"16","author":"J Schaefers","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"M Nickel","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"811686","DOI":"10.3389\/fneur.2022.811686","article-title":"Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview","volume":"13","author":"A Simonati","year":"2022","journal-title":"Front Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","article-title":"Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations","volume":"112","author":"R Steinfeld","year":"2002","journal-title":"Am J Med Genet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","article-title":"Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function","volume":"8","author":"A Orlin","year":"2013","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.oret.2020.01.011","article-title":"Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease","volume":"4","author":"K D Kovacs","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/a-2510-5592","article-title":"Intravitreal enzyme replacement therapy slows retinopathy in late infantile ceroid lipofuscinosis type 2","author":"C S Priglinger","year":"2025","journal-title":"Neuropediatrics"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(23)00384-8","article-title":"Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study","volume":"23","author":"A Schulz","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejpn.2020.12.002","article-title":"Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort","volume":"30","author":"B Estublier","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5935\/0004-2749.20170053","article-title":"Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype","volume":"80","author":"E MAB Quagliato","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1136\/bjo-2022-321260","article-title":"Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)","volume":"107","author":"S Dulz","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref20","first-page":"91","article-title":"Batten disease\u2013deteriorating course of ocular findings","volume":"36","author":"M Horiguchi","year":"1992","journal-title":"Jpn J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2013.08.008","article-title":"Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes","volume":"50","author":"R H Jadav","year":"2014","journal-title":"Pediatr Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcdb.2019.11.003","article-title":"Under pressure: Cerebrospinal fluid contribution to the physiological homeostasis of the eye","volume":"102","author":"S Mirra","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/febs.16330","article-title":"The blood-retina barrier in health and disease","volume":"290","author":"F O\u02bcLeary","year":"2023","journal-title":"FEBS J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"108135","DOI":"10.1016\/j.exer.2020.108135","article-title":"Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis","volume":"198","author":"R EH Whiting","year":"2020","journal-title":"Exp Eye Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.exer.2016.09.003","article-title":"Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis","volume":"152","author":"C J Tracy","year":"2016","journal-title":"Exp Eye Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41433-023-02859-4","article-title":"First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy","volume":"38","author":"J Wawrzynski","year":"2024","journal-title":"Eye (Lond)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/ICU.0000000000001029","article-title":"Intravitreal enzyme replacement for inherited retinal diseases","volume":"35","author":"A C Rodriguez-Martinez","year":"2024","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2528-7886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T23:41:35Z","timestamp":1742859695000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2528-7886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2528-7886","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}